SurModics Announces First Patient Enrolled in IDE Study of SurVeil™ Drug-Coated Balloon

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–SurModics today announced enrollment of the first patient in an early feasibility study of its proprietary SurVeil™ drug-coated balloon.
Source: BusinessWire-Primary

SurModics Announces First Patient Enrolled in IDE Study of SurVeil™ Drug-Coated Balloon